Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Gastroenterology and Hepatology 3, 22–23 (1 January 2006) | doi:10.1038/ncpgasthep0371
Are higher doses of rifaximin more effective for the treatment of small-intestinal bacterial overgrowth?
&
Abstract
Lauritano EC et al. (2005) Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol 22: 31–35 Synopsis Background Patients with small-intestinal bacterial overgrowth (SIBO) receive treatment with antibiotics; however, only a limited number of studies have been performed to determine the optimal choice and duration of antibiotic therapy for these patients.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
